BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Finland's Nexstim Announces New Financing Totaling EUR 6 Million


3/26/2009 8:00:25 AM

HELSINKI--(BUSINESS WIRE)--Nexstim Oy, a medical device company developing non-invasive brain imaging technologies, today announced that it has secured approximately EUR 6 million from existing shareholders and TEKES, the Finnish Funding Agency for Technology and Innovation. To date, Nexstim has raised EUR 20 million, of which approximately EUR 14 million in the last two years.

Nexstim’s existing investors have agreed to subscribe to a EUR 3 million loan based convertible bond. Investors include HealthCap and LSP (Life Sciences Partners), as well as Sitra and Finnish Industry Investment Ltd. Nexstim also received grants and loans of EUR 2.72 million from TEKES to fund a research and clinical development program in stroke.

Jukka-Pekka Särkkä, Managing Director of Nexstim commented, "These are important investments for Nexstim. The new financing enables us to finalize our application to the U.S. Food and Drug Administration (FDA) for marketing clearance of the NBS System in the world’s largest healthcare market. The TEKES funding will help significantly accelerate our program for NBS in stroke."

About Nexstim and NBS Nexstim was founded in 2000 to commercialize Navigated Brain Stimulation (NBS), the combination of stereotactic MRI-guided transcranial magnetic stimulation (TMS) and EEG/EMG response measurement. With NBS, an operator moves a hand-held TMS coil over a patient´s head to deliver a series of short pulses to briefly activate the upper layer of the brain. Responses in the patient´s muscles, measured by EMG, reveal the critical motor areas in the cortex. A standard MR-image of the brain structure allows stereotactic navigation and the NBS system displays the exact location of the electric field in a 3D image of the patient’s brain. The operator can change the field location by moving the coil anywhere over the patient’s head - much like driving with GPS. NBS is safe and completely non-invasive.

NBS has multiple applications in functional brain diagnostics, including cortical mapping prior to surgery and evaluating brain damage following stroke. Therapeutic applications in stroke also hold great promise for NBS. See: http://www.nexstim.com

NBS System is CE-marked. Caution: in the United States the NBS System is limited by Federal law to investigational use.

Contact:

Mr. Jukka-Pekka Särkkä Managing Director Nexstim Oy Mobile +358 40 538 9593 jukka-pekka.sarkka@nexstim.com

Read at BioSpace.com

Nexstim
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES